diABZI STING agonist-1

Name: diABZI STING agonist-1
Brand: MedChemExpress
SKU: HY-112921A
Rating: 5.0 (47 reviews)

Cat. No.: HY-112921A Purity: 99.86%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

diABZI STING agonist-1 is a tautomerism of diABZI STING agonist-1 tautomerism (HY-112921). diABZI STING agonist-1 is a selective stimulator of interferon genes (STING) receptor agonist, with EC₅₀s of 130, 186 nM for human and mouse, respectively.

For research use only. We do not sell to patients.

CAS No. : 2138299-33-7

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 47 publication(s) in Google Scholar

Other Forms of diABZI STING agonist-1:

diABZI STING agonist-1 (tautomerism) In-stock
diABZI STING agonist-1 trihydrochloride In-stock

47 Publications Citing Use of MCE diABZI STING agonist-1

In Vivo Efficacy Study

Histological Imaging/Staining

RT-PCR

: diABZI STING agonist-1 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Apr;12(14):e2417686. [Abstract]; Immunoblot assays of p-IRF3 and p-STING from hPBMCs administrated with CA (10 µM) for 1 h followed by treatment with HT-DNA, cGAMP, or diABZI (10 μg/mL) for 2 h.

: diABZI STING agonist-1 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Apr;12(14):e2417686. [Abstract]; qPCR analysis of IFNB, ISG15, IL-6, and TNF-α mRNA levels from hPBMCs pretreated with CA (10 µM) for 1 h followed by treatment with HT-DNA, cGAMP, or diABZI (10 μg/mL) for 4 h.

: diABZI STING agonist-1 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Apr;12(14):e2417686. [Abstract]; Immunofluorescence analysis of nuclear translocation of IRF3 from THP-1 cells pretreated with vehicle control (DMSO, 1000x) or CA (10 µM) for 1 h followed by administration with diABZI (10 µg mL−1) for 2 h.

: diABZI STING agonist-1 purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2022 Oct 28:547:215885.; Treatment with diABZI (3 mg/kg, i.p.) significantly hindered BAP1 knockdown tumor growth over the course of treatment.

: diABZI STING agonist-1 purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2022 Oct 28:547:215885.; IHC revealed no differences in CD31 staining, but an increase in CD45 staining was observed in the diABZI (3 mg/kg, i.p.)-treated tumors.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

STING^[1].

In Vitro

diABZI STING agonist-1 (compound 3) is a selective stimulator of interferon genes (STING) receptor agonist, with EC₅₀s of 130, 186 nM for human and mouse, respectively. At a concentration of 1 μM, diABZI STING agonist-1 (compound 3) demonstrates high selectivity against more than 350 kinases tested^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

diABZI STING agonist-1 (subcutaneous injection; 2.5 mg/kg) induces STING-dependent activation of type-I interferon and pro-inflammatory cytokines in vivo^[1].
diABZI STING agonist-1 (intravenous injection; 3 mg/kg) exhibits systemic exposure with a half-life of 1.4 h and achieves systemic concentrations greater than the half-maximal effective concentration (EC₅₀) for mouse STING (200 ng/ml)^[1].
diABZI STING agonist-1 (intravenous injection; 1.5 mg/kg; days 1, 4 and 8; 43 days) results in significant tumour growth inhibition and significantly improves survival (P < 0.001) with 8 out of 10 mice remaining tumor free at the end of the study on day 43^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Wild and Sting^−/− C57Blk6 mice^[1]
Dosage:	2.5 mg/kg
Administration:	Subcutaneous injection; 2.5 mg/kg
Result:	Activated secretion of IFNβ, IL-6, TNF, and CXCL1 in wild-type but not Sting^−/− mice.

Animal Model:	Syngeneic mouse model of colorectal tumours (CT-26) in BALB/c mice^[1]
Dosage:	3 mg/kg
Administration:	Intravenous injection; 3 mg/kg
Result:	Exhibited a half-life of 1.4 hours and achieved systemic concentrations greater than EC₅₀ for mouse STING (200 ng/ml).

Animal Model:	Syngeneic mouse model of colorectal tumours (CT-26) in BALB/c mice^[1]
Dosage:	1.5 mg/kg
Administration:	Intravenous injection; 1.5 mg/kg; 43 days
Result:	Resulted in significant tumour growth inhibition and improved survival.

Molecular Weight

849.94

Formula

C₄₂H₅₁N₁₃O₇

CAS No.

2138299-33-7

Appearance

Solid

Color

White to off-white

SMILES

O=C(N)C1=CC(N=C(NC(C2=CC(C)=NN2CC)=O)N3C/C=C/CN4C(NC(C5=CC(C)=NN5CC)=O)=NC6=C4C(OCCCN7CCOCC7)=CC(C(N)=O)=C6)=C3C(OC)=C1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (117.66 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.1766 mL	5.8828 mL	11.7655 mL
5 mM	0.2353 mL	1.1766 mL	2.3531 mL
10 mM	0.1177 mL	0.5883 mL	1.1766 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 3.5 mg/mL (4.12 mM); Clear solution

This protocol yields a clear solution of ≥ 3.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (35.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 3.5 mg/mL (4.12 mM); Clear solution

This protocol yields a clear solution of ≥ 3.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (35.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.86%

Select Batch:

Data Sheet (286 KB) SDS (394 KB)

COA (264 KB) HNMR (501 KB) LCMS (93 KB)

Handling Instructions (2659 KB)

References

[1]. Ramanjulu JM, et al. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature. 2018 Nov 7. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.1766 mL	5.8828 mL	11.7655 mL	29.4138 mL
	5 mM	0.2353 mL	1.1766 mL	2.3531 mL	5.8828 mL
	10 mM	0.1177 mL	0.5883 mL	1.1766 mL	2.9414 mL
	15 mM	0.0784 mL	0.3922 mL	0.7844 mL	1.9609 mL
	20 mM	0.0588 mL	0.2941 mL	0.5883 mL	1.4707 mL
	25 mM	0.0471 mL	0.2353 mL	0.4706 mL	1.1766 mL
	30 mM	0.0392 mL	0.1961 mL	0.3922 mL	0.9805 mL
	40 mM	0.0294 mL	0.1471 mL	0.2941 mL	0.7353 mL
	50 mM	0.0235 mL	0.1177 mL	0.2353 mL	0.5883 mL
	60 mM	0.0196 mL	0.0980 mL	0.1961 mL	0.4902 mL
	80 mM	0.0147 mL	0.0735 mL	0.1471 mL	0.3677 mL
	100 mM	0.0118 mL	0.0588 mL	0.1177 mL	0.2941 mL